Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Smithbridge Asset Management Inc. DE

Smithbridge Asset Management Inc. DE reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,303 shares of the biopharmaceutical company’s stock after selling 572 shares during the period. Smithbridge Asset Management Inc. DE’s holdings in Regeneron Pharmaceuticals were worth $3,472,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in Regeneron Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after acquiring an additional 91,956 shares in the last quarter. Capital World Investors raised its stake in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after buying an additional 23,146 shares in the last quarter. Capital International Investors raised its stake in Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares in the last quarter. Putnam Investments LLC lifted its stake in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after purchasing an additional 24,329 shares during the last quarter. Finally, Norges Bank acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $932,571,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. Evercore ISI started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target on the stock. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Argus increased their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Barclays raised their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Truist Financial reaffirmed a “buy” rating and set a $1,200.00 price objective (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,097.05.

Regeneron Pharmaceuticals Trading Up 0.3 %

NASDAQ:REGN traded up $3.98 on Friday, reaching $1,179.31. The stock had a trading volume of 564,438 shares, compared to its average volume of 483,981. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,185.09. The company has a market cap of $130.01 billion, a price-to-earnings ratio of 34.84, a P/E/G ratio of 3.06 and a beta of 0.13. The firm’s fifty day moving average is $1,070.90 and its two-hundred day moving average is $995.36. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the previous year, the firm posted $8.79 EPS. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now directly owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold a total of 17,731 shares of company stock valued at $18,230,142 over the last quarter. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.